Assenagon Asset Management S.A. Sells 58,663 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Assenagon Asset Management S.A. cut its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 18.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 255,602 shares of the medical research company’s stock after selling 58,663 shares during the period. Assenagon Asset Management S.A.’s holdings in IQVIA were worth $50,228,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Canada Pension Plan Investment Board increased its holdings in IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after buying an additional 211,653 shares during the period. Farallon Capital Management LLC boosted its position in shares of IQVIA by 3.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after acquiring an additional 86,870 shares in the last quarter. FMR LLC increased its stake in IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after acquiring an additional 804,963 shares during the period. JPMorgan Chase & Co. raised its position in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Finally, Impax Asset Management Group plc boosted its holdings in IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after purchasing an additional 157,809 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Price Performance

Shares of IQV stock opened at $196.01 on Thursday. The firm has a market cap of $35.58 billion, a price-to-earnings ratio of 25.72, a PEG ratio of 2.05 and a beta of 1.48. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock has a 50-day moving average price of $201.43 and a 200 day moving average price of $221.61.

Analyst Ratings Changes

A number of brokerages have recently issued reports on IQV. The Goldman Sachs Group dropped their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Robert W. Baird cut their price objective on IQVIA from $213.00 to $212.00 and set a “neutral” rating for the company in a report on Wednesday, December 11th. Stephens began coverage on shares of IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price on the stock. Leerink Partners reissued an “outperform” rating and set a $248.00 price target (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Finally, Morgan Stanley decreased their price objective on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $255.82.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.